These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32628625)

  • 1. Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data.
    Kim S; Chang J; Kim SK; Park S; Huh J; Jeong TD
    Clin Chem Lab Med; 2020 Jul; 59(1):127-138. PubMed ID: 32628625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the CLSI EP26-A protocol for detection of reagent lot-to-lot differences.
    Katzman BM; Ness KM; Algeciras-Schimnich A
    Clin Biochem; 2017 Sep; 50(13-14):768-771. PubMed ID: 28322754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research and discussion on the evaluation scheme of reagent lot-to-lot differences in 16 chemiluminescence analytes, established by the EP26-A guidelines of the CLSI.
    Tao R; Zhang C; Liu M; Yang M; Gao W; Chen J; Mo N; Cheng Y; He J; Xie Q
    J Clin Lab Anal; 2021 Mar; 35(3):e23675. PubMed ID: 33274497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Centralization of multisite reagent lot-to-lot validation for Ortho Clinical Vitros chemistry instruments.
    To M; Raizman JE; Goudreau BL; Higgins T; Brun M; Tsui AKY
    Clin Biochem; 2021 Nov; 97():62-66. PubMed ID: 34343576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical validation of reagent lot change in the clinical chemistry laboratory can confer insights on good clinical laboratory practice.
    Cho MC; Kim SY; Jeong TD; Lee W; Chun S; Min WK
    Ann Clin Biochem; 2014 Nov; 51(Pt 6):688-94. PubMed ID: 24497612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commutability limitations influence quality control results with different reagent lots.
    Miller WG; Erek A; Cunningham TD; Oladipo O; Scott MG; Johnson RE
    Clin Chem; 2011 Jan; 57(1):76-83. PubMed ID: 21097677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations in using the EFLM WG-A/ISO approach for assessment of reagent lot variability.
    Bayat H; Johansen JV; Bachmann L; Person N
    Clin Chem Lab Med; 2023 Oct; 61(11):e215-e217. PubMed ID: 37255006
    [No Abstract]   [Full Text] [Related]  

  • 8. In reply to: Limitations in using the EFLM WG-A/ISO approach for assessment of reagent lot variability.
    Thelen MHM; van Schrojenstein Lantman M; Boursier G; Vanstapel F; Panteghini M
    Clin Chem Lab Med; 2023 Oct; 61(11):e218-e220. PubMed ID: 37261942
    [No Abstract]   [Full Text] [Related]  

  • 9. Lot-to-Lot Variation.
    Thompson S; Chesher D
    Clin Biochem Rev; 2018 May; 39(2):51-60. PubMed ID: 30473592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lot-to-lot variation and verification.
    Loh TP; Markus C; Tan CH; Tran MTC; Sethi SK; Lim CY
    Clin Chem Lab Med; 2023 Apr; 61(5):769-776. PubMed ID: 36420533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lot verification practices in Ontario clinical chemistry laboratories - Results of a patterns-of-practice survey.
    Rutledge AC; Johnston A; Booth RA; Veljkovic K; Bailey D; Vandenberghe H; Waite G; Allen LC; Don-Wauchope A; Chan PC; Stemp J; Edmond P; Leung V; Aslan B
    Pract Lab Med; 2022 Nov; 32():e00300. PubMed ID: 36035320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting long-term drift in reagent lots.
    Liu J; Tan CH; Loh TP; Badrick T
    Clin Chem; 2015 Oct; 61(10):1292-8. PubMed ID: 26272234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of reagent lot-to-lot comparability tests in five immunoassay items.
    Kim HS; Kang HJ; Whang DH; Lee SG; Park MJ; Park JY; Lee KM
    Ann Clin Lab Sci; 2012; 42(2):165-73. PubMed ID: 22585613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions.
    Algeciras-Schimnich A; Bruns DE; Boyd JC; Bryant SC; La Fortune KA; Grebe SK
    Clin Chem; 2013 Aug; 59(8):1187-94. PubMed ID: 23592508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of internal quality control in detecting significant reagent lot shift in serum creatinine measurement.
    Chen X; Wang J; Zhang W; Xie E; Zhang B; Xu HG
    J Clin Lab Anal; 2019 Nov; 33(9):e22991. PubMed ID: 31373724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selecting methods of controls concentration for internal quality control and continuity of control chart between different reagent lots for HBsAg qualitative detection].
    Li JM; Zheng HJ; Wang LN; Deng W
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):228-31. PubMed ID: 12716523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Importance of Reagent Lot Registration in External Quality Assurance/Proficiency Testing Schemes.
    Stavelin A; Riksheim BO; Christensen NG; Sandberg S
    Clin Chem; 2016 May; 62(5):708-15. PubMed ID: 26980211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lot-to-lot reagent verification: challenges and possible solutions.
    Loh TP; Sandberg S; Horvath AR
    Clin Chem Lab Med; 2022 Apr; 60(5):675-680. PubMed ID: 35191278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size for equivalence trials: a case study from a vaccine lot consistency trial.
    Ganju J; Izu A; Anemona A
    Stat Med; 2008 Aug; 27(19):3743-54. PubMed ID: 18416439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified quality control protocol for infectious disease serology based on the Westgard rules.
    Wang Y; Li X; Li D; Xie Y
    Sci Rep; 2024 Jul; 14(1):16683. PubMed ID: 39030224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.